斑蝥酸钠注射液治疗癌性胸腔积液的临床观察

Clinical Observation on Treatment of Cancerous Hydrothorax by Aiyishu injection

目的探讨斑蝥酸钠注射液治疗癌性胸腔积液的疗效、对患者生存质量的影响及其细胞免疫功能变化。方法60例合并胸腔积液的晚期癌症患者,随机分为试验组和对照组,每组30例。对所有患者行胸腔穿刺引流胸腔积液后,试验组患者胸腔给予斑蝥酸钠注射液50ml治疗,并同时静脉注射斑蝥酸钠50ml,每天1次,连续15天。对照组患者胸腔应用化疗药物或白介素2治疗。3天后,均再次行穿刺给药治疗1次;4周后,应用B超定量测定两组患者的胸腔积液量,评价胸腔积液治疗的疗效;并对两组患者的生存质量、体重及其治疗前后T淋巴细胞亚群等进行比较。结果试验组患者的胸腔积液疗效明显提高(P <0 . 0 1) ,生存质量明显提高(P <0 . 0 5)。试验组患者外周血CD3 +、CD4+、CD4+/CD8+较治疗前提高(P <0. 0 1)。两组比较CD3 +、CD4+明显升高,CD8+明显降低及CD4+/CD8+比值明显升高,差异均有显著性(P<0 . 0 5或P <0 . 0 1)。结论斑蝥酸钠注射液是一种治疗癌症患者胸腔积液,改善患者生存质量,提高机体细胞免疫功能的良好中草药制剂。且胸腔与静脉同时使用比单独胸腔注射效果为好。

ObjectiveTo investigate the therapeutic effects of Aiyishu Injection (AYSI) on cancerous hydrothorax, quality of life (QOF), and cellular immune function of patients. MethodsSixty late-stage cancer patients accompanied hydrothorax were randomly divided into the experimental group (EG) and the control group (CG), with thirty patients in each group. After thoracenteses being carried out in all patients for draining off hydropsy, to the patients in EG, AYSI was medicated, 50 ml by intrathoracic and another 50 ml by intravenous injection; while to the patients in CG chemotherapeutic agent or interleukin-2 (IL-2) was given. The same treatment, thoracentesis and medication, was repeated 3 days later. After 4 weeks, the volume of pleural effusion was measured with B-mode ultrasound to evaluate the therapeutic effects of AYSI. QOF, body weight and T-lymphocyte subsets were compared between the two groups before and after treatment. ResultsThe clinical efficacy was significantly higher in EG than that in CG (P<0.01). Besides, QOF was significantly improved(P<0.05) and levels of CD_3 +, CD_4 +, CD_4 +/CD_8 + in peripheral blood increased in EG after treatment, which were significantly different to those in CG (P<0.01, P<0.05). ConclusionAYSI has definite therapeutic effects on cancerous hydrothorax, it could improve QOF and cellular immune function in patients with cancer.